High cost of insulin and treatment
Insulin underpins diabetes treatment for approximately 8.4 million people worldwide living with type 1 diabetes. For more than 60 million people living with type 2 diabetes, insulin is essential to reduce the risk of diabetes-related complications like chronic kidney disease (CKD), cardiovascular disease (CVD), retinopathy and nerve disease.
The US has some of the highest insulin prices in the world. A single vial of insulin can cost over USD 300 without health insurance. This exorbitant cost forces some people to ration insulin, leading to dangerous health consequences such as diabetic ketoacidosis (DKA), which can be fatal. Although efforts have been made in the past eight years to cap the price of insulin, the cost is still not accessible to everyone. Meanwhile, in many Caribbean nations, access to insulin is often limited, and public healthcare systems struggle with supply shortages, leaving people with diabetes reliant on inconsistent imports or expensive private options.
Several countries in the Caribbean region have established free or low-cost insulin distribution programmes to improve access for people with diabetes. Furthermore, the Organization of Eastern Caribbean States (OECS) has implemented the Diabetes Prevention and Care Project, which focuses on diabetes prevention, reducing diabetes-related complications, and supporting the development of a regional diabetes registry. Beneficiary countries include Antigua and Barbuda, Dominica, Grenada, Saint Lucia, and Saint Vincent and the Grenadines.
Similarly, in Haiti, IDF partner Direct Relief, in collaboration with the Haiti Health Network, has elaborated transportation channels to ensure the delivery of insulin and supplies in difficult-to-reach areas in the north of the island.
Additionally, the WHO Global Diabetes Compact works to improve global insulin access by collaborating with governments to lower costs and expand distribution efforts, ensuring that more people in LMICs receive essential diabetes care.
Beyond insulin, people with diabetes use glucose monitors, test strips, insulin pumps and continuous glucose monitors (CGMs) to manage their condition. However, these essential devices can be prohibitively expensive without health insurance. A CGM can cost over USD 1,200 per year out-of-pocket, making it inaccessible for many people in low-income environments.
With diabetes management supplies scarce in some Caribbean nations, people rely on methods predating technological advancements, such as manual blood glucose testing. Although considered innovative for its time, this can lead to less effective monitoring and increased risk for complications.